Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Background: Multiple myeloma (MM) patients are at risk of skeletal-related events (SREs) like spinal cord compression, pathologic fractures, bone surgery, and radiation to bone. Realworld data regarding SREs in MM are limited.
Methods: We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service (HIRA) database from 2007 to 2018.
Results: Over a 12-year study period, we identified 6,717 patients who developed symptomatic MM. After a median follow-up of 35.1 months (interquartile range [IQR], 20.8–58.2 months), 43.6% of these patients experienced SREs, and 39.6% had four or more SREs. One in five patients (20.0%) experienced pathologic fractures within the first year of follow-up. The median time to first SRE was 9.6 months (IQR, 1.2–25.8 months), with 3.0 months in the group with prior SREs and 19.8 months in the group without prior SREs.
During follow-up, 78.5% of patients received bisphosphonates. Multiple logistic regression analysis revealed several factors associated with an increased risk of SREs, including being female (odds ratio [OR], 1.44), aged 50 or older (OR, 1.87), having cerebrovascular disease (OR, 1.34), undergoing first-line chemotherapy regimens not containing bortezomib or lenalidomide (OR, 1.49), and being in the group with prior SREs and bisphosphonate use (OR, 5.63), compared to the group without prior SREs and without bisphosphonate use.
Conclusion: This population-based study is the first to report the incidence and risk factors of SREs in Korean MM patients, which can be used to assess their bone health.

번역하기

참고문헌 (Reference)

1 Qian Y, "Utilization patterns of bone-targeting agents among patients with multiple myeloma : analysis of real-world data" 126 (126): 4501-, 2015

2 Terpos E, "Treatment of multiple myeloma-related bone disease : recommendations from the Bone Working Group of the International Myeloma Working Group" 22 (22): e119-e130, 2021

3 Ramsenthaler C, "The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma : a multi-centre study" 16 (16): 427-, 2016

4 Ashcroft J, "Skeletal-related events in myeloma : a population-based study" 122 (122): 3158-, 2013

5 Coleman RE, "Skeletal complications of malignancy" 80 (80): 1588-1594, 1997

6 Garrett IR, "Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro" 111 (111): 1771-1782, 2003

7 Terpos E, "Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease" 24 (24): 1043-1049, 2010

8 Kim C, "Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA : observations from real-world data" 26 (26): 2833-2841, 2018

9 안승희 ; 박상민 ; 0000-0002-4820-9415 ; 유준일 ; Hyoung Seok Jung ; 노재휘 ; Se Hwa Kim ; 이영균 ; Yong-Chan Ha ; 장선미 ; 김태영 ; 김하영, "Osteoporosis and osteoporotic fracture fact sheet in Korea" 27 (27): 281-290, 2020

10 Roodman GD, "Novel targets for myeloma bone disease" 12 (12): 1377-1387, 2008